Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00591396 · ClinicalTrials.gov registry record · Phase 1

A Phase I Trial of ZIO-101 in Solid Tumors

A Phase 1 study, sponsored by Alaunos Therapeutics.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00591396 is a Phase 1 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00591396, a Phase 1 study, has completed, sponsored by Alaunos Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors

Interventions

  • DRUG ZIO-101 (Darinaparsin)

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2005-07
Est. Completion 2008-07
Phase Phase 1

Sponsor

Alaunos Therapeutics

22 total trials

What the Registry Record Tells You About NCT00591396

The ClinicalTrials.gov registry entry for NCT00591396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ZIO-101 (Darinaparsin) is the first listed.

NCT00591396 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00591396 about?

NCT00591396 is a clinical study titled "A Phase I Trial of ZIO-101 in Solid Tumors". A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors

What is the current status of trial NCT00591396?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-07. Estimated completion is 2008-07.

What interventions are being tested in trial NCT00591396?

The interventions under investigation include: ZIO-101 (Darinaparsin) (DRUG).

Who is sponsoring clinical trial NCT00591396?

This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.